Organoid and pluripotent stem cells in Parkinson’s disease modeling: an expert view on their value to drug discovery

Nick Marotta, Soojin Kim, Dimitri Krainc*

*Corresponding author for this work

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Introduction: Parkinson’s disease is a devastating neurodegenerative disorder preferentially involving loss of dopaminergic neurons in the substantia nigra, leading to typical motor symptoms. While there are still no therapeutics to modify disease course, recent work using induced pluripotent stem cell (iPSC) and 3D brain organoid models have provided further insight into Parkinson’s disease pathogenesis and potential therapeutic targets. Areas covered: This review highlights the generation of iPSC neurons and neural organoids as models for studying Parkinson’s disease. It further discusses the recent work using patient-derived neurons from both familial and sporadic forms of Parkinson’s to study disease pathogenic phenotypes and pathways. It additionally provides an evaluation of iPSC neurons and organoid models for therapeutic development in Parkinson’s. Expert opinion: The use of Parkinson’s disease patient-derived neurons and organoids provides us with the exciting opportunity to directly investigate pathogenic mechanisms and test drug compounds in human neurons. Future studies will involve generating more sophisticated models of brain organoids, studying neuronal pathways using larger patient cohorts, and routinely assessing therapeutics in these models.

Original languageEnglish (US)
Pages (from-to)427-441
Number of pages15
JournalExpert Opinion on Drug Discovery
Volume15
Issue number4
DOIs
StatePublished - Apr 2 2020

Keywords

  • dopaminergic neurons
  • GBA
  • Induced pluripotent stem cells
  • midbrain
  • neurodegeneration
  • organoid
  • Parkinson’s disease
  • therapeutics
  • α-synuclein

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'Organoid and pluripotent stem cells in Parkinson’s disease modeling: an expert view on their value to drug discovery'. Together they form a unique fingerprint.

  • Cite this